

ARCC

Canadian Centre
for Applied Research
in Cancer Control

A Draft Reassessment Framework Developed by the CanREValue Collaboration

Alex Chambers
Director, pCODR
CADTH
May 28, 2019



BC Cancer Agency
CARE & RESEARCH
An agency of the Provincial Health Services Authority



**SIMON FRASER
UNIVERSITY**
ENGAGING THE WORLD

a place of mind



**UNIVERSITY OF
TORONTO**

Cancer Care Ontario
Action Cancer Ontario



**Canadian
Cancer
Society** **Société
canadienne
du cancer**

CanREValue Goal

Overall Purpose

To develop a framework for Canadian provinces to generate and use RWE for cancer drug funding decisions in a consistent and integrated manner

Potential System Impact

- Reassessment of cancer drugs by recommendation-makers
- Refinement of funding decisions or re-negotiations/re-investment by decision-makers/payers across Canada




Value-based decisions from Real World Evidence


CanREValue Objectives

No.	Objective
1	To develop a comprehensive understanding of the current state of RWE in cancer drug reimbursement in Canada
2	To establish formal national working groups dedicated to policy and methodological applications of RWE, and collaboratively/iteratively develop working framework for the generation and use of RWE
3	To validate the developed framework through the completion of multi-province RWE projects
4	To employ knowledge translation (KT) strategies to establish and integrate the final RWE framework into official practice of participating provinces and on a national level

National Working Groups (WG)



Reassessment WG Membership



RWE Uptake and Reassessment WG

- **Objectives:**

1. to propose a high-level process for how the reassessment of currently funded drugs could work within the Canadian health system
2. to recommend processes and factors required to revisit negotiations and funding decisions

Scope of the Reassessment WG

In Scope

- Define a high-level process for reassessments
- How to initiate reassessment of drugs
- How/who will conduct reassessments
- What information is required to revise a funding decision?


Out of Scope

- Guidance on the critical appraisal of RWE
- Triggers for selecting drugs for RWE data collection
- How RWE data are going to be collected
- How RWE analysis will be conducted
- Provincial infrastructure for RWE

Methods

- A modified Delphi approach was used to inform the reassessment and uptake component of the framework.
- Series of surveys/teleconferences to seek areas of agreement on how a reassessment framework could be conceptualized

DRAFT Reassessment Process



* CADTH or another national group

Current Status and Next Steps

- Draft report on draft reassessment framework that has been reviewed by the Working Group
- Explore draft reassessment framework with other working groups, in particular the stakeholder working group
- Conduct a 'mock reassessment' to see how the draft reassessment framework performs—identifying gaps and opportunities

Thank you

